You just read:

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer

News provided by

Merrimack Pharmaceuticals, Inc.

May 19, 2016, 07:00 ET